Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Danaher Corp. net fixed asset turnover ratio deteriorated from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Danaher Corp. total asset turnover ratio deteriorated from Q3 2023 to Q4 2023 but then slightly improved from Q4 2023 to Q1 2024. |
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Danaher Corp. equity turnover ratio deteriorated from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |
Net Fixed Asset Turnover
Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Sales | 5,796) | 3,911) | 6,873) | 7,157) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | 8,148) | 7,229) | 7,218) | 6,858) | 6,760) | 5,883) | 5,297) | 4,343) | 4,868) | 4,378) | 4,445) | 4,220) | |||||||
Property, plant and equipment, net of accumulated depreciation | 4,562) | 4,553) | 4,302) | 4,176) | 4,065) | 3,956) | 3,719) | 3,794) | 3,815) | 3,790) | 3,640) | 3,410) | 3,266) | 3,262) | 3,052) | 2,973) | 2,989) | 2,302) | 2,520) | 2,542) | 2,504) | |||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Net fixed asset turnover1 | 5.20 | 5.25 | 6.59 | 6.98 | 7.31 | 7.96 | 8.40 | 8.12 | 7.94 | 7.77 | 7.71 | 7.84 | 7.59 | 6.83 | 6.68 | 6.35 | 6.03 | 7.78 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | — | 10.89 | 11.18 | 11.33 | 11.51 | 11.76 | 11.82 | 11.57 | 11.18 | 11.00 | 10.75 | 10.41 | 9.67 | 8.73 | 8.15 | 7.38 | 11.50 | 11.23 | — | — | — | |||||||
Amgen Inc. | — | 4.53 | 4.61 | 4.58 | 4.56 | 4.57 | 4.73 | 4.77 | 4.75 | 4.69 | 4.89 | 4.92 | 4.93 | 4.96 | 4.94 | 4.78 | 4.68 | 4.51 | — | — | — | |||||||
Bristol-Myers Squibb Co. | 6.75 | 6.77 | 6.93 | 7.11 | 7.30 | 7.38 | 7.74 | 7.90 | 7.77 | 7.67 | 7.75 | 7.66 | 7.43 | 7.22 | 6.86 | 6.03 | 5.07 | 4.18 | — | — | — | |||||||
Eli Lilly & Co. | 2.64 | 2.64 | 2.70 | 2.62 | 2.63 | 2.81 | 3.14 | 3.18 | 3.22 | 3.15 | 3.11 | 3.02 | 2.95 | 2.83 | 2.80 | 2.88 | 2.92 | 2.83 | — | — | — | |||||||
Gilead Sciences Inc. | — | 5.07 | 4.88 | 4.91 | 4.88 | 4.93 | 5.01 | 5.13 | 5.18 | 5.27 | 5.40 | 5.27 | 5.06 | 4.90 | 4.74 | 4.70 | 4.90 | 4.91 | — | — | — | |||||||
Johnson & Johnson | 4.36 | 4.28 | 4.86 | 4.56 | 4.58 | 4.79 | 5.29 | 5.21 | 5.07 | 4.95 | 4.95 | 4.79 | 4.59 | 4.40 | 4.53 | 4.57 | 4.75 | 4.65 | — | — | — | |||||||
Merck & Co. Inc. | — | 2.61 | 2.63 | 2.62 | 2.66 | 2.77 | 2.89 | 2.85 | 2.73 | 2.53 | 2.57 | 2.61 | 2.55 | 2.67 | 2.80 | 2.99 | 3.15 | 3.11 | — | — | — | |||||||
Pfizer Inc. | — | 3.09 | 3.84 | 4.46 | 5.45 | 6.17 | 6.47 | 6.64 | 6.12 | 5.46 | 4.79 | 3.89 | 3.31 | 3.01 | 2.98 | 3.21 | 3.47 | 3.71 | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | — | 3.16 | 3.27 | 3.23 | 3.19 | 3.23 | 3.70 | 3.91 | 4.64 | 4.62 | 3.99 | 3.69 | 2.82 | 2.64 | 2.63 | 2.64 | 2.71 | 2.72 | — | — | — | |||||||
Thermo Fisher Scientific Inc. | — | 4.54 | 4.74 | 4.68 | 4.68 | 4.84 | 5.12 | 5.02 | 4.87 | 4.71 | 5.54 | 5.83 | 5.85 | 5.45 | 5.50 | 5.37 | 5.42 | 5.38 | — | — | — | |||||||
Zoetis Inc. | — | 2.67 | 2.71 | 2.73 | 2.78 | 2.93 | 3.05 | 3.12 | 3.17 | 3.21 | 3.26 | 3.24 | 3.15 | 3.03 | 3.12 | 3.15 | 3.21 | 3.23 | — | — | — |
Based on: 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).
1 Q1 2024 Calculation
Net fixed asset turnover
= (SalesQ1 2024
+ SalesQ4 2023
+ SalesQ3 2023
+ SalesQ2 2023)
÷ Property, plant and equipment, net of accumulated depreciation
= (5,796 + 3,911 + 6,873 + 7,157)
÷ 4,562 = 5.20
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Danaher Corp. net fixed asset turnover ratio deteriorated from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |
Total Asset Turnover
Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Sales | 5,796) | 3,911) | 6,873) | 7,157) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | 8,148) | 7,229) | 7,218) | 6,858) | 6,760) | 5,883) | 5,297) | 4,343) | 4,868) | 4,378) | 4,445) | 4,220) | |||||||
Total assets | 83,402) | 84,488) | 87,734) | 84,902) | 85,040) | 84,350) | 81,030) | 81,806) | 83,392) | 83,184) | 82,498) | 78,027) | 75,426) | 76,161) | 72,891) | 71,268) | 68,930) | 62,082) | 61,531) | 53,322) | 51,774) | |||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Total asset turnover1 | 0.28 | 0.28 | 0.32 | 0.34 | 0.35 | 0.37 | 0.39 | 0.38 | 0.36 | 0.35 | 0.34 | 0.34 | 0.33 | 0.29 | 0.28 | 0.27 | 0.26 | 0.29 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | — | 0.40 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.40 | 0.40 | 0.38 | 0.37 | 0.36 | 0.33 | 0.30 | 0.27 | 0.24 | 0.37 | 0.37 | — | — | — | |||||||
Amgen Inc. | — | 0.28 | 0.28 | 0.28 | 0.28 | 0.38 | 0.38 | 0.41 | 0.41 | 0.40 | 0.37 | 0.40 | 0.38 | 0.39 | 0.37 | 0.36 | 0.37 | 0.37 | — | — | — | |||||||
Bristol-Myers Squibb Co. | 0.46 | 0.47 | 0.49 | 0.48 | 0.49 | 0.48 | 0.48 | 0.47 | 0.46 | 0.42 | 0.41 | 0.40 | 0.38 | 0.36 | 0.31 | 0.27 | 0.24 | 0.20 | — | — | — | |||||||
Eli Lilly & Co. | 0.56 | 0.53 | 0.55 | 0.54 | 0.52 | 0.58 | 0.62 | 0.62 | 0.62 | 0.58 | 0.58 | 0.56 | 0.54 | 0.53 | 0.53 | 0.55 | 0.56 | 0.57 | — | — | — | |||||||
Gilead Sciences Inc. | — | 0.43 | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.40 | 0.41 | 0.39 | 0.37 | 0.36 | 0.37 | 0.39 | 0.37 | 0.36 | — | — | — | |||||||
Johnson & Johnson | 0.50 | 0.51 | 0.55 | 0.49 | 0.47 | 0.51 | 0.55 | 0.54 | 0.53 | 0.52 | 0.51 | 0.51 | 0.49 | 0.47 | 0.47 | 0.51 | 0.53 | 0.52 | — | — | — | |||||||
Merck & Co. Inc. | — | 0.56 | 0.56 | 0.56 | 0.54 | 0.54 | 0.55 | 0.53 | 0.51 | 0.46 | 0.51 | 0.52 | 0.51 | 0.52 | 0.53 | 0.52 | 0.57 | 0.55 | — | — | — | |||||||
Pfizer Inc. | — | 0.26 | 0.32 | 0.35 | 0.48 | 0.51 | 0.51 | 0.52 | 0.50 | 0.45 | 0.39 | 0.33 | 0.29 | 0.27 | 0.24 | 0.25 | 0.29 | 0.31 | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | — | 0.40 | 0.41 | 0.41 | 0.41 | 0.42 | 0.50 | 0.52 | 0.63 | 0.63 | 0.57 | 0.58 | 0.52 | 0.50 | 0.51 | 0.55 | 0.51 | 0.53 | — | — | — | |||||||
Thermo Fisher Scientific Inc. | — | 0.43 | 0.45 | 0.46 | 0.46 | 0.46 | 0.49 | 0.47 | 0.44 | 0.41 | 0.53 | 0.57 | 0.54 | 0.47 | 0.44 | 0.43 | 0.44 | 0.44 | — | — | — | |||||||
Zoetis Inc. | — | 0.60 | 0.59 | 0.60 | 0.59 | 0.54 | 0.59 | 0.58 | 0.57 | 0.56 | 0.56 | 0.53 | 0.51 | 0.49 | 0.48 | 0.49 | 0.55 | 0.54 | — | — | — |
Based on: 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).
1 Q1 2024 Calculation
Total asset turnover
= (SalesQ1 2024
+ SalesQ4 2023
+ SalesQ3 2023
+ SalesQ2 2023)
÷ Total assets
= (5,796 + 3,911 + 6,873 + 7,157)
÷ 83,402 = 0.28
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Danaher Corp. total asset turnover ratio deteriorated from Q3 2023 to Q4 2023 but then slightly improved from Q4 2023 to Q1 2024. |
Equity Turnover
Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Sales | 5,796) | 3,911) | 6,873) | 7,157) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | 8,148) | 7,229) | 7,218) | 6,858) | 6,760) | 5,883) | 5,297) | 4,343) | 4,868) | 4,378) | 4,445) | 4,220) | |||||||
Total Danaher stockholders’ equity | 53,442) | 53,486) | 52,407) | 51,716) | 51,478) | 50,082) | 46,985) | 46,594) | 46,356) | 45,167) | 43,451) | 42,756) | 40,419) | 39,766) | 37,961) | 36,262) | 31,055) | 30,271) | 32,502) | 32,201) | 31,557) | |||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Equity turnover1 | 0.44 | 0.45 | 0.54 | 0.56 | 0.58 | 0.63 | 0.67 | 0.66 | 0.65 | 0.65 | 0.65 | 0.62 | 0.61 | 0.56 | 0.54 | 0.52 | 0.58 | 0.59 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | — | 5.24 | 4.56 | 4.35 | 4.27 | 3.36 | 3.62 | 3.91 | 3.48 | 3.65 | 4.07 | 4.27 | 3.66 | 3.50 | 2.66 | 2.46 | — | — | — | — | — | |||||||
Amgen Inc. | — | 4.32 | 3.35 | 3.73 | 4.66 | 6.77 | 6.71 | 10.17 | 26.68 | 3.63 | 2.96 | 2.93 | 2.56 | 2.58 | 2.17 | 2.17 | 2.41 | 2.30 | — | — | — | |||||||
Bristol-Myers Squibb Co. | 2.76 | 1.53 | 1.55 | 1.41 | 1.44 | 1.49 | 1.43 | 1.45 | 1.49 | 1.29 | 1.22 | 1.21 | 1.14 | 1.12 | 0.79 | 0.71 | 0.62 | 0.51 | — | — | — | |||||||
Eli Lilly & Co. | 2.80 | 3.17 | 2.86 | 2.67 | 2.47 | 2.68 | 2.90 | 3.40 | 3.14 | 3.15 | 3.58 | 4.15 | 3.69 | 4.35 | 4.81 | 5.61 | 7.50 | 8.56 | — | — | — | |||||||
Gilead Sciences Inc. | — | 1.18 | 1.22 | 1.28 | 1.27 | 1.27 | 1.27 | 1.34 | 1.37 | 1.28 | 1.27 | 1.34 | 1.33 | 1.34 | 1.31 | 1.21 | 1.01 | 0.98 | — | — | — | |||||||
Johnson & Johnson | 1.22 | 1.24 | 1.28 | 1.25 | 1.30 | 1.24 | 1.29 | 1.25 | 1.27 | 1.27 | 1.30 | 1.28 | 1.28 | 1.31 | 1.25 | 1.28 | 1.35 | 1.38 | — | — | — | |||||||
Merck & Co. Inc. | — | 1.60 | 1.44 | 1.51 | 1.24 | 1.29 | 1.33 | 1.32 | 1.32 | 1.28 | 1.33 | 1.41 | 1.73 | 1.90 | 1.62 | 1.71 | 1.83 | 1.81 | — | — | — | |||||||
Pfizer Inc. | — | 0.66 | 0.71 | 0.79 | 0.92 | 1.05 | 1.08 | 1.16 | 1.12 | 1.05 | 0.91 | 0.79 | 0.68 | 0.66 | 0.66 | 0.70 | 0.75 | 0.82 | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | — | 0.51 | 0.53 | 0.53 | 0.53 | 0.54 | 0.64 | 0.69 | 0.83 | 0.86 | 0.78 | 0.82 | 0.77 | 0.77 | 0.81 | 0.88 | 0.66 | 0.71 | — | — | — | |||||||
Thermo Fisher Scientific Inc. | — | 0.92 | 0.96 | 0.99 | 1.04 | 1.02 | 1.01 | 1.01 | 1.00 | 0.96 | 1.01 | 1.04 | 1.02 | 0.93 | 0.90 | 0.88 | 0.90 | 0.86 | — | — | — | |||||||
Zoetis Inc. | — | 1.71 | 1.65 | 1.78 | 1.80 | 1.83 | 1.72 | 1.75 | 1.69 | 1.71 | 1.63 | 1.70 | 1.71 | 1.77 | 1.82 | 2.13 | 2.30 | 2.31 | — | — | — |
Based on: 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).
1 Q1 2024 Calculation
Equity turnover
= (SalesQ1 2024
+ SalesQ4 2023
+ SalesQ3 2023
+ SalesQ2 2023)
÷ Total Danaher stockholders’ equity
= (5,796 + 3,911 + 6,873 + 7,157)
÷ 53,442 = 0.44
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Danaher Corp. equity turnover ratio deteriorated from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |